Literature DB >> 29923637

Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.

C Holly A Andrilla1, Tessa E Moore1, Davis G Patterson1, Eric H Larson1.   

Abstract

PURPOSE: Opioid use disorder (OUD) is a substantial public health problem. Buprenorphine is an effective medication-assisted treatment (MAT) for OUD, but access is difficult for patients, especially in rural locations. To improve access, the Comprehensive Addiction and Recovery Act of 2016 extended the ability to get a Drug Enforcement Administration (DEA) waiver to prescribe buprenorphine to treat OUD to nurse practitioners (NPs) and physician assistants (PAs). This study summarizes the geographic distribution of waivered physicians, NPs, and PAs at the end of 2017 and compares it to the distribution of waivered physicians 5 years earlier.
METHODS: Using the DEA list of providers with a waiver to prescribe buprenorphine to treat OUD and the Area Health Resources File, we assigned waivered providers to counties in 1 of 4 geographic categories. We calculated the number of counties in each category that did not have a waivered provider and county provider to population ratios and then compared our results to the waivered workforce in 2012.
FINDINGS: The availability of a physician with a DEA waiver to provide office-based MAT has increased across all geographic categories since 2012. More than half of all rural counties (56.3%) still lack a provider, down from 67.1% in 2012. Almost one-third (29.8%) of rural Americans compared to 2.2% of urban Americans live in a county without a buprenorphine provider. NPs and PAs add otherwise lacking treatment availability in 56 counties (43 rural).
CONCLUSIONS: Overall, MAT access has improved, but rural communities still experience treatment disparities.
© 2018 National Rural Health Association.

Entities:  

Keywords:  buprenorphine; medication-assisted treatment; opioid treatment programs; opioid use disorder; rural health

Mesh:

Substances:

Year:  2018        PMID: 29923637     DOI: 10.1111/jrh.12307

Source DB:  PubMed          Journal:  J Rural Health        ISSN: 0890-765X            Impact factor:   4.333


  86 in total

1.  West Virginia's model of buprenorphine expansion: Preliminary results.

Authors:  Erin L Winstanley; Laura R Lander; James H Berry; James J Mahoney; Wanhong Zheng; Jeremy Herschler; Patrick Marshalek; Sheena Sayres; Jay Mason; Marc W Haut
Journal:  J Subst Abuse Treat       Date:  2019-05-08

2.  Geographic location of buprenorphine-waivered physicians and integration with health systems.

Authors:  Brendan Saloner; LeeKai Lin; Kosali Simon
Journal:  J Subst Abuse Treat       Date:  2020-05-12

3.  Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.

Authors:  Babak Tofighi; Arthur Robin Williams; Chemi Chemi; Selena Suhail-Sindhu; Vicky Dickson; Joshua D Lee
Journal:  Subst Use Misuse       Date:  2019-08-20       Impact factor: 2.164

4.  ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.

Authors:  Ryan Marino; Jeanmarie Perrone; Lewis S Nelson; Timothy J Wiegand; Evan S Schwarz; Paul M Wax; Andrew I Stolbach
Journal:  J Med Toxicol       Date:  2019-08-14

Review 5.  The United States opioid epidemic.

Authors:  Jennifer Lyden; Ingrid A Binswanger
Journal:  Semin Perinatol       Date:  2019-01-14       Impact factor: 3.300

6.  Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study.

Authors:  Tamara Beetham; Brendan Saloner; Sarah E Wakeman; Marema Gaye; Michael L Barnett
Journal:  Ann Intern Med       Date:  2019-06-04       Impact factor: 25.391

7.  Opioid Use Disorder Treatment Facilities With Programs for Special Populations.

Authors:  Scott E Hadland; Victoria A Jent; Rachel H Alinsky; Brandon D L Marshall; Pia M Mauro; Magdalena Cerdá
Journal:  Am J Prev Med       Date:  2020-05-21       Impact factor: 5.043

8.  Federal Barriers to Addressing the Opioid Epidemic.

Authors:  Robert A Kleinman; Nathaniel P Morris
Journal:  J Gen Intern Med       Date:  2020-02-19       Impact factor: 5.128

9.  Polysubstance Use Patterns among Justice-Involved Individuals Who Use Opioids.

Authors:  Amanda M Bunting; Carrie Oser; Michele Staton; Hannah Knudsen
Journal:  Subst Use Misuse       Date:  2020-07-20       Impact factor: 2.164

10.  Impact of health reform on health insurance status among persons who use opioids in eastern Kentucky: A prospective cohort analysis.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Sharon L Walsh; Jennifer R Havens
Journal:  Int J Drug Policy       Date:  2019-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.